• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    6/6/24 4:31:11 PM ET
    $AEMD
    $APDN
    $BGXX
    $BMEA
    Medical/Dental Instruments
    Health Care
    Other Consumer Services
    Consumer Discretionary
    Get the next $AEMD alert in real time by email

    Gainers

    • Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 8.58% to $2.15. The market value of their outstanding shares is at $3.1 million.
    • Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 8.27% to $0.59. The market value of their outstanding shares is at $6.0 million.
    • Kiora Pharmaceuticals (NASDAQ:KPRX) shares rose 5.0% to $0.45. The market value of their outstanding shares is at $11.9 million.
    • Fractyl Health (NASDAQ:GUTS) shares moved upwards by 4.94% to $6.79. The market value of their outstanding shares is at $325.2 million.
    • Rallybio (NASDAQ:RLYB) shares rose 4.69% to $1.56. The company's market cap stands at $64.6 million.

    Losers

    • Biomea Fusion (NASDAQ:BMEA) stock fell 61.9% to $4.3 during Thursday's after-market session. The company's market cap stands at $154.5 million.
    • Tevogen Bio Holdings (NASDAQ:TVGN) stock fell 13.49% to $0.77. The company's market cap stands at $127.9 million.
    • Bright Green (NASDAQ:BGXX) stock fell 8.55% to $0.32. The market value of their outstanding shares is at $61.0 million.
    • Trevi Therapeutics (NASDAQ:TRVI) shares decreased by 6.89% to $2.3. The market value of their outstanding shares is at $162.0 million.
    • Aethlon Medical (NASDAQ:AEMD) stock fell 6.84% to $0.51. The company's market cap stands at $2.6 million.
    • Onconetix (NASDAQ:ONCO) shares decreased by 6.46% to $0.17. The market value of their outstanding shares is at $3.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $APDN
    $BGXX
    $BMEA

    CompanyDatePrice TargetRatingAnalyst
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2026Buy → Hold
    D. Boral Capital
    Fractyl Health Inc.
    $GUTS
    1/30/2026$2.00Overweight → Equal-Weight
    Morgan Stanley
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    Trevi Therapeutics Inc.
    $TRVI
    11/13/2025$13.00Outperform
    Leerink Partners
    Fractyl Health Inc.
    $GUTS
    9/15/2025$9.00Buy
    H.C. Wainwright
    Biomea Fusion Inc.
    $BMEA
    8/28/2025$5.00Buy
    Jefferies
    Fractyl Health Inc.
    $GUTS
    8/28/2025$3.60Buy
    Ladenburg Thalmann
    Trevi Therapeutics Inc.
    $TRVI
    8/21/2025$18.00Overweight
    Morgan Stanley
    More analyst ratings

    $AEMD
    $APDN
    $BGXX
    $BMEA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

    CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that its Board of Directors (the "Board of Directors" or "Board") has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026. On February 3, 2026, Onconetix held a special meeting of stockholders (the "Special Meeting"), at which the Company's stockholders approved a proposal to effect a reverse split, at a ratio in

    3/23/26 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

    WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026), taking place March 16–20, 2026, in Atlanta, Georgia. Mr. Mehta will participate in two sessions focused on the evolving intersection of data engineering and artificial intelligence: From Risk to Reward: Modernizing the Data Estate to Power Enterprise AIWednesday, March 18, 4:30PM – 5:05PM alongside Dipti Borkar, VP & GM OneLake & ISVs at Microsoft and Tripti Sethi, Data & AI Lead at Avanade.Agentic Data Engineering on Micr

    3/18/26 12:22:11 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

    Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig

    3/17/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $APDN
    $BGXX
    $BMEA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tevogen Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Tevogen Bio from Buy to Hold

    3/4/26 9:36:27 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fractyl Health downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Fractyl Health from Overweight to Equal-Weight and set a new price target of $2.00

    1/30/26 6:42:49 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Rodman & Renshaw initiated coverage on Biomea Fusion with a new price target

    Rodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00

    1/13/26 10:18:10 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $APDN
    $BGXX
    $BMEA
    SEC Filings

    View All

    SEC Form PRE 14A filed by Onconetix Inc.

    PRE 14A - Onconetix, Inc. (0001782107) (Filer)

    3/18/26 7:55:08 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fractyl Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

    3/17/26 4:30:08 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Trevi Therapeutics Inc.

    10-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

    3/17/26 4:08:55 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $APDN
    $BGXX
    $BMEA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Flomenberg Neal sold $6,635 worth of shares (972 units at $6.83), decreasing direct ownership by 1% to 76,940 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    3/17/26 4:29:13 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Kiora Pharmaceuticals Inc.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:36:21 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kiora Pharmaceuticals Inc.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:37:12 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $APDN
    $BGXX
    $BMEA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Erdtmann Rainer M bought $42,999 worth of shares (30,000 units at $1.43), increasing direct ownership by 4% to 723,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/15/25 4:15:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rajagopalan Harith bought $19,999 worth of shares (10,416 units at $1.92), increasing direct ownership by 2% to 501,745 units (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/8/25 7:05:03 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $APDN
    $BGXX
    $BMEA
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

    WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month. Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients. Tevogen continues to prioritize the development of TVGN 489,

    3/11/26 3:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Names Leadership Team to Execute Diversified Growth Strategy

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek StobinskiGene

    3/9/26 7:45:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $APDN
    $BGXX
    $BMEA
    Financials

    Live finance-specific insights

    View All

    Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

    Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig

    3/17/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

    BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Health         Fractyl Health is a clinical stage met

    3/17/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

    Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive.Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen's lead investor, directors and named executive officers.Company prioritizing long-term stock-based incentive program aligned with company milestones.Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.Company continues to evaluate acquisitions that could generate

    3/13/26 2:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $APDN
    $BGXX
    $BMEA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/14/24 5:51:58 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care